Back to Search
Start Over
Anti-EGFR-Based Therapy in Recurrent or Metastatic HNSCC – What Difference Does it Make?
- Source :
- Cancer Investigation. 41:93-100
- Publication Year :
- 2022
- Publisher :
- Informa UK Limited, 2022.
-
Abstract
- Patients with R/M HNSCC treated with palliative first-line therapy at Hannover Medical School between October 2005 and December 2016 have been included to show changes in survival following broad utilization of cetuximab. Treatment periods were defined from 10/2005 to 12/2008 (Period A) and 01/2009 to 12/2016. Overall survival did not improve over time. However, in subgroup analysis cetuximab utilized at any time vs. never showed a significant improve of overall survival (11.3 vs. 6.3 months, HR: 0.55, 95%-CI: 0.4-0.8
- Subjects :
- Cancer Research
Oncology
Medizin
General Medicine
Subjects
Details
- ISSN :
- 15324192 and 07357907
- Volume :
- 41
- Database :
- OpenAIRE
- Journal :
- Cancer Investigation
- Accession number :
- edsair.doi.dedup.....5da0143c8c89bee313282fbce9cd64c5